Helio Genomics Welcomes Dr. Bharat Tewarie as New CEO to Drive AI Cancer Detection Innovations
In a significant move for the field of cancer diagnostics, Helio Genomics has announced the appointment of Dr. Bharat Tewarie as its new Chief Executive Officer. This decision marks a critical step in the company’s mission to enhance the capabilities of AI-powered, blood-based cancer diagnostics. With an extensive background in healthcare leadership, Dr. Tewarie brings decades of valuable experience, particularly in the commercialization and scaling of innovative diagnostics technologies.
Justin Li, the company’s previous CEO since 2021, will transition to the role of President, ensuring continued leadership in Helio's long-term strategies and innovation efforts. In his announcement, Li expressed excitement about Dr. Tewarie’s appointment, highlighting the essential role he will play in guiding the company through its forthcoming growth journey. 'Leading Helio through its growth journey has been the honor of a lifetime,' Li stated. 'I'm excited to welcome Bharat, whose deep expertise and bold vision will be valuable as we enter our next chapter.'
Dr. Tewarie's impressive career includes pivotal roles in top-tier companies across the life sciences sector, including UCB, Merck KGaA, Roche, and Boehringer Ingelheim. He has held executive leadership roles that encompass all facets of operations, from commercial strategy to scientific advancements, alongside prior experience leading startups in the biopharma and medical device sectors. Dr. Tewarie's passion lies in the intersection of artificial intelligence and data science, particularly in their application to healthcare—a belief that aligns perfectly with Helio’s aspirations.
Upon accepting his new role, Dr. Tewarie remarked, 'I am honored to join Helio and accelerate its growth as our AI-driven diagnostics have the potential to redefine global cancer care. Together, we will bring innovative solutions to more healthcare providers and patients to detect liver cancer early and hence save lives.' His commitment reflects the company's dedication to advancing scientific excellence and improving patient outcomes through innovative, AI-powered solutions.
Notably, Helio Genomics has established a remarkable platform for early cancer detection that is clinically validated and backed by significant patient studies. The company's flagship product, HelioLiver Dx, is a groundbreaking multi-analyte blood test designed to detect early-stage hepatocellular carcinoma (HCC) in individuals at risk due to liver cirrhosis or Hepatitis B. The test utilizes machine learning and advanced analytics on cfDNA and serum protein markers, achieving superior sensitivity to traditional ultrasound methods, significantly enhancing early detection capabilities.
With a Clinical Laboratory Improvement Amendments (CLIA) certification and a proprietary laboratory analyses (PLA) code from the American Medical Association, HelioLiver is poised to streamline access to this life-saving technology across the United States. The test's clinical trials, notably the ENCORE and CLiMB studies, have demonstrated its efficacy in accurately identifying liver cancer, making it a transformative option for patients and healthcare providers alike.
The leadership change at Helio symbolizes not just a shift in personnel but also a renewed focus on harnessing technology to enhance cancer care. With a firm commitment to innovation, the company aims to facilitate greater accessibility and adoption of its advanced diagnostic solutions. Helio Genomics stands as a promising leader in the race to combat cancer, and under Dr. Tewarie’s guidance, it is set to forge a path towards redefining cancer detection standards on a global scale.
Justin Li, the company’s previous CEO since 2021, will transition to the role of President, ensuring continued leadership in Helio's long-term strategies and innovation efforts. In his announcement, Li expressed excitement about Dr. Tewarie’s appointment, highlighting the essential role he will play in guiding the company through its forthcoming growth journey. 'Leading Helio through its growth journey has been the honor of a lifetime,' Li stated. 'I'm excited to welcome Bharat, whose deep expertise and bold vision will be valuable as we enter our next chapter.'
Dr. Tewarie's impressive career includes pivotal roles in top-tier companies across the life sciences sector, including UCB, Merck KGaA, Roche, and Boehringer Ingelheim. He has held executive leadership roles that encompass all facets of operations, from commercial strategy to scientific advancements, alongside prior experience leading startups in the biopharma and medical device sectors. Dr. Tewarie's passion lies in the intersection of artificial intelligence and data science, particularly in their application to healthcare—a belief that aligns perfectly with Helio’s aspirations.
Upon accepting his new role, Dr. Tewarie remarked, 'I am honored to join Helio and accelerate its growth as our AI-driven diagnostics have the potential to redefine global cancer care. Together, we will bring innovative solutions to more healthcare providers and patients to detect liver cancer early and hence save lives.' His commitment reflects the company's dedication to advancing scientific excellence and improving patient outcomes through innovative, AI-powered solutions.
Notably, Helio Genomics has established a remarkable platform for early cancer detection that is clinically validated and backed by significant patient studies. The company's flagship product, HelioLiver Dx, is a groundbreaking multi-analyte blood test designed to detect early-stage hepatocellular carcinoma (HCC) in individuals at risk due to liver cirrhosis or Hepatitis B. The test utilizes machine learning and advanced analytics on cfDNA and serum protein markers, achieving superior sensitivity to traditional ultrasound methods, significantly enhancing early detection capabilities.
With a Clinical Laboratory Improvement Amendments (CLIA) certification and a proprietary laboratory analyses (PLA) code from the American Medical Association, HelioLiver is poised to streamline access to this life-saving technology across the United States. The test's clinical trials, notably the ENCORE and CLiMB studies, have demonstrated its efficacy in accurately identifying liver cancer, making it a transformative option for patients and healthcare providers alike.
The leadership change at Helio symbolizes not just a shift in personnel but also a renewed focus on harnessing technology to enhance cancer care. With a firm commitment to innovation, the company aims to facilitate greater accessibility and adoption of its advanced diagnostic solutions. Helio Genomics stands as a promising leader in the race to combat cancer, and under Dr. Tewarie’s guidance, it is set to forge a path towards redefining cancer detection standards on a global scale.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.